Skip to Main Content

Observations, lessons, and takeaways from Monday’s failure of Gilead Sciences’ (GILD) NASH drug, selonsertib.

1. In defense of Gilead, a broad swath of Wall Street’s covering analysts argued the negative outcome of the Phase 3 study was expected and therefore already baked into the biotech’s diminished stock price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.